September 2025 - Page 2 of 4 - BioMedWire (BMW)

FridaySep 19, 2025 10:00 am

UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy

A grant of $2 million has been awarded to UCLA Health by a for-profit company, ViewRay Systems. The purpose of this grant is to enable the university to accelerate its research efforts in finding ways in which MRI-guided radiation therapy can be leveraged to provide targeted treatment to cancer patients. Cancer treatments, such as radiation and chemotherapy, are known to impact both diseased and healthy tissues. The impact on healthy tissue causes a variety of side effects, such as hair loss and weight loss, which can affect the health and quality of life of patients. Efforts have therefore been made…

ThursdaySep 18, 2025 10:00 am

New Research Suggests Dietary Change Could Improve Glioblastoma Treatment Outcomes

Researchers at the University of Michigan have published a study which suggests that implementing a dietary adjustment could make glioblastoma, a deadly type of brain cancer, more susceptible to chemotherapy and radiation treatments targeting the tumors in the brain. The study, whose findings appeared in the Nature journal on September 3, suggests that when scientists gain deep understanding of the different mechanisms through which tumor cells alter their metabolic systems inside a patient to boost the proliferation of the tumor, it could unlock novel ways to fight this cancer that has so far been very difficult to treat. Professor Costas…

WednesdaySep 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

On the global stage, the Cancer Atlas estimates a dramatic rise in cancer cases, adding urgency to the need for therapeutic innovation Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases This year, the company achieved a major milestone by successfully completing a phase 1 clinical trial evaluating OT-101 combining Interleukin-2 In a landscape where cancer and underserved diseases continue to devastate millions, the demand for groundbreaking RNA-based, immunotherapeutic, and targeted treatments has never been more urgent. Oncotelic Therapeutics (OTCQB: OTLC) is answering this call with pioneering RNA candidates and strategic programs aimed at…

TuesdaySep 16, 2025 10:00 am

New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease

UCLA researchers have developed a smart pen that can detect Parkinson’s during its early stages when the symptoms relied upon for the usual way to diagnose it haven’t shown up yet. Initial tests of this pen revealed an accuracy rate of 96.22%. Currently, Parkinson’s is usually detected when it has advanced so much that it is difficult for existing medications to have any impact in slowing down its progression. This smart pen developed by the UCLA researchers offers an affordable and accessible way to leverage simple acts like writing on a piece of paper to detect the disease long before…

TuesdaySep 16, 2025 9:45 am

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Clene Inc. reported new preclinical data on its drug candidate CNM-Au8 for Parkinson’s disease. The therapy improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized gene expression in dopaminergic neurons. Findings were presented at the Michael J. Fox Foundation’s H2 Therapeutics Stewardship Meeting in New York City. CNM-Au8 previously showed positive energetic and metabolic effects in a Phase 2 Parkinson’s trial, aligning with the new preclinical results. The treatment demonstrated no toxicity in neuronal models, consistent with safety data from over 1,000 patient-years in ALS and MS trials. Clene plans to design a Phase 2 clinical study for Parkinson’s…

FridaySep 12, 2025 2:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): When 15 Years of Data Creates Unassailable AI Advantage

Proprietary machine-learning reconstruction algorithm trained on 15 years of breast CT data positions IzoView to redefine global imaging standards Self-supervised approach works on X-ray data before reconstruction, avoiding the delays that cripple competing AI methods Trade secret protection and modality-specific training create durable competitive moats in a crowded, commoditized AI field The medical imaging industry stands at a pivotal juncture. Artificial intelligence promises to revolutionize diagnostics, yet most AI applications in CT imaging remain stuck in theory rather than practice. Conventional AI denoising tools either demand prohibitive computing power, compromise diagnostic clarity, or require impractical training datasets that increase patient…

FridaySep 12, 2025 12:30 pm

HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch

Company releases report updating status of proprietary 12-lead ECG synthesis software for arrhythmia assessment. Earlier this year, HeartBeam submitted its software application to the U.S. Food and Drug Administration. Plans will ensure that healthcare providers and patients can seamlessly integrate the HeartBeam system into clinical workflows and home-monitoring routines. In its most recent quarterly update, HeartBeam (NASDAQ: BEAT) is reporting that the company is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. The company is actively preparing for FDA 510(k) clearance of its innovative 12-lead ECG synthesis software for arrhythmia assessment while executing comprehensive commercial readiness…

FridaySep 12, 2025 10:00 am

Study Finds That Common Sweetener Could Compromise Cancer Treatment Effectiveness

Researchers at University of Pittsburg have found that patients who consume sucralose regularly have a lower likelihood of benefiting from immunotherapy and having longer survival times. Sucralose is an artificial sweetener that is commonly used in a variety of diet products, such as Splenda. This research is the first to connect the dietary choices that people make to groundbreaking cancer treatments. For their study, the team obtained the dietary data of 91 patients diagnosed with advanced melanoma. They also obtained similar data from 41 patients having lung cancer. The patients whose daily intake of sucralose exceeded 0.07mg for each pound…

ThursdaySep 11, 2025 12:45 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Exclusive CADx Patent Positions IzoView as First-Mover in AI-Enhanced Breast CT

Exclusive U.S. patent rights for computer-aided diagnosis (“CADx”) with breast CT secured through a global license with the University of California CADx planned as a post-market software upgrade, creating dual revenue streams via upgrade incentives and licensing Patent exclusivity paired with proprietary machine-learning reconstruction establishes a durable moat in dedicated breast imaging The AI Integration Challenge in Medical Imaging Artificial intelligence has long promised to revolutionize radiology, but most applications remain stuck between theoretical potential and real-world limitations. CADx systems can enhance detection, yet they face hurdles: lack of specialized datasets, workflow disruptions, and intellectual property barriers. In breast imaging,…

ThursdaySep 11, 2025 12:00 pm

Adageis Simplifies Value-Based Care with AI Platform Focused on Financial Gain, Increased Visibility

Adageis provides AI-powered healthcare software designed to simplify value-based care adoption. The company’s patented ProActive Care Platform integrates with leading electronic health record (“EHR”) systems. The platform emphasizes simplicity, visibility into insurance contracts, and long-term financial gain for providers. Providers can use the system to identify high-value services, track reimbursements, and manage complex contracts. Adageis currently covers more than 260,000 patient lives, with ongoing growth expected. Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. By focusing on…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: September 2025

UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy

New Research Suggests Dietary Change Could Improve Glioblastoma Treatment Outcomes

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): When 15 Years of Data Creates Unassailable AI Advantage

HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch

Study Finds That Common Sweetener Could Compromise Cancer Treatment Effectiveness

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Exclusive CADx Patent Positions IzoView as First-Mover in AI-Enhanced Breast CT

Adageis Simplifies Value-Based Care with AI Platform Focused on Financial Gain, Increased Visibility

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search